Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

Product Sheet

H_CDH17 LLC1 Cell Line

Catalog number: GM-C31642

Version 3.3.1.241029

Description	H_CDH17 LLC1 Cell Line is a clonal stable LLC1 cell line constitutively expressing human CDH17.
Quantity	5E6 Cells per vial,1 mL
Product Format	3 vials of frozen cells
Shipping	Shipped on dry ice
Storage Conditions	Liquid nitrogen immediately upon receipt
Target	Human_CDH17
Gene ID/Uniprot ID	Q12864(AA Met 1 - Ile 808)
Host Cell	LLC1
Recovery Medium	DMEM+10% FBS+1% P.S
Growth medium	DMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+1 μg/mL Puromycin
Note	None
Freezing Medium	90% FBS+10% DMSO
Growth properties	Mixed: adherent and suspension
Growth Conditions	37°C, 5% CO_2
Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.
Safety considerations	Biosafety Level 2
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

Materials

Reagent	Manufacturer/Catalogue No.
DMEM	Gibco/C11995500BT
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
Pen/Strep	Thermo/15140-122
Blasticidin	Genomeditech/GM-040404
Puromycin	Genomeditech/GM-040401
Anti-CDH17 hIgG1 Antibody(BI-905711)	Genomeditech/GM-52672AB

Figures



SampleID	Geometric Mean : FL11-H
LLC1 anti-CDH17+APC-2nd Ab	2529
LLC1 H_CDH17 H_IgG+APC-2nd Ab	2486
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #13	117541
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #17	92283
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #18	121592

Figure 1 | H_CDH17 LLC1 Cell Line #13, H_CDH17 LLC1 Cell Line #17 and H_CDH17 LLC1 Cell Line #18 were determined by flow cytometry using Anti-CDH17 hIgG1 Antibody (Cat. GM-52672AB).



SampleID	Geometric Mean : FL11-H
LLC1 anti-CDH17+APC-2nd Ab	2407
LLC1 H_CDH17 H_IgG+APC-2nd Ab	2105
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #13 CP3	109610
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #13 CP8	38748
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #13 CP13	22373

Figure 2 | The passage stability of the H_CDH17 LLC1 Cell Line #13 was determined by flow cytometry using Anti-CDH17 hIgG1 Antibody(BI-905711) (Cat. GM-52672AB).

High passage H_CDH17 LLC1 Cell Line #13 may demonstrate diminished signaling capabilities during culture, a phenomenon intricately linked to cellular senescence, alterations in gene expression, and reduced intercellular interactions.

Consequently, it is advisable to prioritize the use of low passage cells to preserve the integrity of their biological characteristics and functions, thereby enhancing the reliability and reproducibility of experimental outcomes.



SampleID	Geometric Mean : FL11-H
LLC1 anti-CDH17+APC-2nd Ab	2364
LLC1 H_CDH17 H_IgG+APC-2nd Ab	3005
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #17 CP3	73036
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #17 CP8	34057
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #17 CP13	49889

Figure 3 | The passage stability of the H_CDH17 LLC1 Cell Line #17 was determined by flow cytometry using Anti-CDH17 hIgG1 Antibody(BI-905711) (Cat. GM-52672AB).

High passage H_CDH17 LLC1 Cell Line #17 may demonstrate diminished signaling capabilities during culture, a phenomenon intricately linked to cellular senescence, alterations in gene expression, and reduced intercellular interactions. Consequently, it is advisable to prioritize the use of low passage cells to preserve the integrity of their biological characteristics and functions, thereby enhancing the reliability and reproducibility of experimental outcomes.



SampleID	Geometric Mean : FL11-H
LLC1 anti-CDH17+APC-2nd Ab	2465
LLC1 H_CDH17 H_IgG+APC-2nd Ab	2535
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #18 CP3	101934
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #18 CP8	41803
LLC1 H_CDH17 anti-CDH17+APC-2nd Ab #18 CP13	47812

Figure 4 | The passage stability of the H_CDH17 LLC1 Cell Line #18 was determined by flow cytometry using Anti-CDH17 hIgG1 Antibody(BI-905711) (Cat. GM-52672AB).

High passage H_CDH17 LLC1 Cell Line #18 may demonstrate diminished signaling capabilities during culture, a phenomenon intricately linked to cellular senescence, alterations in gene expression, and reduced intercellular interactions. Consequently, it is advisable to prioritize the use of low passage cells to preserve the integrity of their biological characteristics and functions, thereby enhancing the reliability and reproducibility of experimental outcomes.

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

Cell Recovery

Recovery Medium: DMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
e) Incubate the culture at 37°C in a suitable incubator. A 5% CO_2 in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a) Centrifuge at 176 x g for 3 minutes to collect cells.
b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
c) Aliquot 1 mL into each vial.
d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: DMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+1 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a) Under normal conditions, these cells exist as both adherent and round suspension cells.
b) When changing the medium, take care to retain the suspension cells. During passaging, collect both the adherent and suspension cells together before subculturing.
c) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 1 to 2 minutes at 37°C).
d) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
e) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
f) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
g) Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a) After the stabilization of the cell condition, there will be fewer dead cells post-passage, the cell growth rate will tend to stabilize, cell morphology will become uniform, and the cells will appear robust.

Sequence

CDH17 Q12864(ΔICD)

MILQAHLHSLCLLMLYLATGYGQEGKFSGPLKPMTFSIYEGQEPSQIIFQFKANPPAVTFELTGETDNIFVIERE
GLLYYNRALDRETRSTHNLQVAALDANGIIVEGPVPITIKVKDINDNRPTFLQSKYEGSVRQNSRPGKPFLYV
NATDLDDPATPNGQLYYQIVIQLPMINNVMYFQINNKTGAISLTREGSQELNPAKNPSYNLVISVKDMGGQSE
NSFSDTTSVDIIVTENIWKAPKPVEMVENSTDPHPIKITQVRWNDPGAQYSLVDKEKLPRFPFSIDQEGDIYVT
QPLDREEKDAYVFYAVAKDEYGKPLSYPLEIHVKVKDINDNPPTCPSPVTVFEVQENERLGNSIGTLTAHDRD
EENTANSFLNYRIVEQTPKLPMDGLFLIQTYAGMLQLAKQSLKKQDTPQYNLTIEVSDKDFKTLCFVQINVIDI
NDQIPIFEKSDYGNLTLAEDTNIGSTILTIQATDADEPFTGSSKILYHIIKGDSEGRLGVDTDPHTNTGYVIIKKP
LDFETAAVSNIVFKAENPEPLVFGVKYNASSFAKFTLIVTDVNEAPQFSQHVFQAKVSEDVAIGTKVGNVTAK
DPEGLDISYSLRGDTRGWLKIDHVTGEIFSVAPLDREAGSPYRVQVVATEVGGSSLSSVSEFHLILMDVNDNP
PRLAKDYTGLFFCHPLSAPGSLIFEATDDDQHLFRGPHFTFSLGSGSLQNDWEVSKINGTHARLSTRHTEFEER
EYVVLIRINDGGRPPLEGIVSLPVTFCSCVEGSCFRPAGHQTGIPTVGMAVGILLTTLLVIGIILAVVFI*

Related Products

CDH3	
Cynomolgus_CDH3 CHO-K1 Cell Line	H_CDH3 CHO-K1 Cell Line
H_CDH3 HEK-293 Cell Line	Anti-H_CDH3 hIgG1 Antibody
CDH6	
Cynomolgus_CDH6 CHO-K1 Cell Line	H_CDH6 CHO-K1 Cell Line
H_CDH6 HEK-293 Cell Line	Anti-H_CDH6 hIgG1 Antibody(H01L02)
Anti-CDH6 hIgG1 Reference Antibody (Ralubio)	
CDH17	
Cynomolgus_CDH17 HEK-293 Cell Line	Cynomolgus_CDH17(XP_005563762.1) HEK-293 Cell Line
H_CDH17 CHO-K1 Cell Line	H_CDH17 CT26 Cell Line
H_CDH17 HCT116 Cell Line	H_CDH17 HEK-293 Cell Line
H_CDH17 MC38 Cell Line	H_CDH17 RKO Cell Line
H_CDH17 SW480 Cell Line	H_CDH17(ΔEC1,Flag-EC2-7) HEK-293 Cell Line
H_CDH17(ΔEC1-2,Flag-EC3-7) HEK-293 Cell Line	H_CDH17(ΔEC1-3,Flag-EC4-7) HEK-293 Cell Line
H_CDH17(ΔEC1-4,Flag-EC5-7) HEK-293 Cell Line	H_CDH17(ΔEC1-5,Flag-EC6-7) HEK-293 Cell Line
H_CDH17(ΔEC1-6,Flag-EC7) HEK-293 Cell Line	Mouse_CDH17 HEK-293 Cell Line
Rat_CDH17 HEK-293 Cell Line	Rhesus_CDH17 HEK-293 Cell Line

Anti-CDH17 hIgG1 Antibody(BI-905711)	Anti-CDH17 hIgG1 Antibody(VHHl-28BB)
Anti-CDH17 hIgG1 Reference Antibody(BI-905711)	Human CDH17 Protein; His Tag
Mouse CDH17 Protein; His Tag	Biotinylated Human CDH17 Protein; His-Avi Tag
Cynomolgus CDH17 Protein; His Tag	

Limited Use License Agreement

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.